About Great Bay Bio
Headquartered in Hong Kong, the CMC/CDMO platform of Great Bay Bio was established in 2002, where originally more than 100 million yuan was invested to build a national level CMC platform. The CMC/CDMO platform has independent and integrated technology platforms for drug R&D and large scale preparation. The company has a strong existing track record of developing customized CMC packages for biologic products, some of which are national class I projects of innovative biological new drugs that have already reached NDA stage.
Great Bay Bio is leveraging on its established platform to develop a new vertical in CMC. Specifically, Great Bay Bio strives to utilize AI and other cutting-edge technologies to shorten CMC development timelines, lower cost, and increase efficiency of CMC. With such a platform, it could expand and acquire new customer base, and brings fundamental changes to drug development, and ultimately benefiting society and patients.
The platform has been recognized and certificated as “Patent Fostering Enterprise”, “Patent Pilot Enterprise”, “National High-tech Enterprise”, “Dongguan New R&D Institution”, “Guangdong Top Ten Foreign-funded R&D Center” and “Guangdong Genetically Pharmaceutical Engineering Research Center”. Since 2006, it has undertaken a number of government projects and obtained crucial breakthroughs in key areas of Guangdong and Hong Kong. More than 20 million yuan have been received from the government to support numerous provincial and national projects, such as “National Major New Drug Innovation”
The CMC platform encompasses an area of over 3100 square meter, and has a whole set of advanced biopharmaceutical research and development hardware, with key equipment from world-class brands such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilot workshop is designed strictly in accordance with cGMP requirements, with cleanroom standards of C-level and partial A-level.
South Africa Today – World News – Asia and Pacific